Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets
Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets
复制标题
DOI：
10.1182/blood.v99.6.2054
复制
发表时间：
2002-03-15
期刊：
影响因子：
20.3
通讯作者：
Aster, RH
中科院分区：
文献类型：
--
作者：
Curtis, BR;Swyers, J;Aster, RH
服用纤维蛋白原受体拮抗剂阿昔单抗（一种含有鼠特异性决定序列和人类框架序列的嵌合 Fab 片段）的患者中，1% 至 2% 的患者会出现血小板减少症，通常很严重。这种并发症的原因尚未确定。对 9 名出现严重血小板减少症（血小板
Thrombocytopenia, often severe, occurs in 1% to 2% of patients given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine specificity-determining and human framework sequences. The cause of this complication has not yet been defined. Studies of 9 patients who developed profound thrombocytopenia (platelets